Targeting IGF-1/2 with xentuzumab plus enzalutamide in metastatic castration-resistant prostate cancer after progression on docetaxel chemotherapy and abiraterone: Randomized phase II trial results
Syed Hussain, José Pablo Maroto, Miguel Ángel Climent, Diletta Bianchini, Robert Hugh Jones, Chia-Chi Lin, Shian-Shiang Wang, Emma Dean, Kate Crossley, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
FOR HEALTHCARE PROFESSIONALS ONLY.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue